| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
46.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6394 - $5.57 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
| Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
49,815 |
194,004 |
265,777 |
1,488,473 |
| Total Sell Value |
$38,529 |
$137,285 |
$313,570 |
$9,885,249 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
20 |
39 |
62 |
109 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-08-17 |
4 |
AS |
$17.82 |
$270,953 |
D/D |
(15,205) |
441,608 |
|
-27% |
|
| Melian Agustin |
Chief Medical Officer |
• – – |
2021-07-02 |
4 |
AS |
$19.99 |
$371,534 |
D/D |
(18,586) |
479,718 |
|
23% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-06-03 |
4 |
AS |
$22.87 |
$11,618 |
D/D |
(508) |
456,813 |
|
-2% |
|
| Brenner Malcolm |
Director |
– • – |
2021-05-25 |
4 |
GD |
$0.00 |
$0 |
I/I |
818,663 |
0 |
|
- |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-05-18 |
4 |
AS |
$22.80 |
$346,583 |
D/D |
(15,201) |
457,321 |
|
6% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2021-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
206,300 |
|
- |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-05-10 |
4 |
S |
$22.75 |
$3,412,500 |
I/I |
(150,000) |
2,309,142 |
|
-9% |
|
| Melian Agustin |
Chief Medical Officer |
• – – |
2021-04-05 |
4 |
AS |
$23.89 |
$435,085 |
D/D |
(18,212) |
498,304 |
|
-22% |
|
| Melian Agustin |
Chief Medical Officer |
• – – |
2021-03-22 |
4 |
AS |
$25.97 |
$97,394 |
D/D |
(3,750) |
516,516 |
|
-25% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-03-16 |
4 |
AS |
$30.00 |
$90,751 |
I/I |
(3,025) |
2,459,142 |
|
-36% |
|
| Wilson John Robert |
Director |
– • – |
2021-03-11 |
4 |
AS |
$30.87 |
$516,729 |
I/I |
(16,662) |
3,164,954 |
|
-41% |
|
| Wilson John Robert |
Director |
– • – |
2021-03-10 |
4 |
AS |
$30.93 |
$2,273,924 |
I/I |
(72,745) |
3,169,120 |
|
-42% |
|
| Wilson John Robert |
Director |
– • – |
2021-03-09 |
4 |
AS |
$31.30 |
$3,477,448 |
I/I |
(110,595) |
3,187,306 |
|
-46% |
|
| Brenner Malcolm |
Director |
– • – |
2021-03-05 |
4 |
AS |
$30.39 |
$1,495,500 |
I/I |
(48,091) |
818,663 |
|
-43% |
|
| Brenner Malcolm |
Director |
– • – |
2021-03-04 |
4 |
AS |
$34.67 |
$1,777,298 |
I/I |
(49,598) |
866,754 |
|
-49% |
|
| Vera Juan |
Director |
– • – |
2021-03-03 |
4 |
AS |
$37.01 |
$612,585 |
D/D |
(15,988) |
2,339,928 |
|
-51% |
|
| Brenner Malcolm |
Director |
– • – |
2021-03-03 |
4 |
AS |
$36.91 |
$679,950 |
I/I |
(17,915) |
916,352 |
|
-51% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-03-02 |
4 |
AS |
$37.93 |
$19,420 |
D/D |
(512) |
472,522 |
|
-50% |
|
| Vera Juan |
Director |
– • – |
2021-03-02 |
4 |
AS |
$37.28 |
$571,396 |
D/D |
(14,994) |
2,355,916 |
|
-50% |
|
| Brenner Malcolm |
Director |
– • – |
2021-03-02 |
4 |
AS |
$37.35 |
$482,388 |
I/I |
(12,658) |
934,267 |
|
-50% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-03-01 |
4 |
AS |
$38.62 |
$230,034 |
D/D |
(5,932) |
488,230 |
|
-49% |
|
| Vera Juan |
Director |
– • – |
2021-03-01 |
4 |
AS |
$38.28 |
$1,267,778 |
D/D |
(32,854) |
2,370,910 |
|
-49% |
|
| Miller Edward |
General Counsel |
• – – |
2021-03-01 |
4 |
AS |
$38.58 |
$232,699 |
I/I |
(6,000) |
192,811 |
|
-49% |
|
| Brenner Malcolm |
Director |
– • – |
2021-03-01 |
4 |
AS |
$38.39 |
$838,227 |
I/I |
(21,694) |
946,925 |
|
-49% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-03-01 |
4 |
AS |
$38.46 |
$368,329 |
I/I |
(9,518) |
2,462,167 |
|
-49% |
|
304 Records found
|
|
Page 9 of 13 |
|
|
